TABLE 3.

Changes in cardiac magnetic resonance measurements and clinical parameters: benchmarked to changes in how a patient “feels” (emPHasis-10 (E-10), n=118), “functions” (incremental shuttle walk test (ISWT), n=146) or “survives” (1-year mortality post-follow-up, n=254)

	Improved		Stable		Worsened
	Baseline	Follow-up	Baseline	Follow-up	Baseline	Follow-up
E-10	n=42		n=55		n=21
E-10 (points)	37±10	21±11	29±12	29±12	24±10	37±7
RVEF (%)	32±12	42±13	34±12	42±10	38±10	43±8
RVEDV (mL)	208±66	182±59	200±78	201±74	174±69	163±57
RVESV (mL)	146±60	110±53	138±68	122±60	112±56	94±40
ISWT	n=57		n=64		n=25
Walk distance (m)	249±181	409±197	197±1501	196±148	259±16	158±142
RVEF (%)	31±10	42±10	34±11	40±10	33±12	38±10
RVEDV (mL)	235±70	216±86	208±79	196±74	187±69	192±70
RVESV (mL)	164±62	128±62	144±68	122±61	129±65	121±55
Mortality	Survivors n=229				Non-survivors n=25
RVEF (%)	34±11	41±11			31±13	36±16
RVEDV (mL)	207±71	195±71			202±79	207±85
RVESV (mL)	141±62	118±56			144±72	139±75

Data are presented as mean±sd, unless otherwise stated. RVEF: right ventricular ejection fraction; RVEDV: right ventricular end-diastolic volume; RVESV: right ventricular end-systolic volume. Measurements were taken at baseline before treatment and at follow-up (12±6 months). Improvement was defined as an increase of at least 47.5 m in the ISWT, a decrease of at least 6 points in the E-10 score and 1 year survival post-follow-up, whereas worsening was defined as a reduction in the ISWT of at least 47.5 m, an increase of 6 points in the E-10 score or mortality. Otherwise, patients were described as stable.